Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 26, 2018Cancer Treatment ReviewsOpen Access

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJean‐Luc RaoulGoethe University Frankfurt
Masatoshi Kudo
Masatoshi KudoKanazawa UniversityRFRichard S. FinnAstraZeneca (United Kingdom)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Raoul et al. (2018) studied this question.

synapsesocial.com/papers/6a802d77485cf8e532e45bfahttps://doi.org/10.1016/j.ctrv.2018.05.006
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective2010 · 979 citations
  2. 2Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies2017 · 582 citations
  3. 3Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial2014 · 638 citations